Agilis Biotherapeutics Updates on Progress in CNS Gene Therapy Programs – Business Wire (press release)
|
Agilis Biotherapeutics Updates on Progress in CNS Gene Therapy Programs
Business Wire (press release) The cohort of patients in the Phase IIb study brings the total number of patients who have received AGIL-AADC to 24, likely representing the largest cohort of patients in any CNS gene therapy program. AADC deficiency is a rare disease of young children … |
